Date post: | 01-Jan-2016 |
Category: |
Documents |
Upload: | evangeline-cox |
View: | 214 times |
Download: | 1 times |
The “Worlds” of FHC
2
Consumer Global Public Sector
Global Market
$4-6 Billion
Family Planning
HIV/AIDS
Global Condom Public Health
$ 400 – 500 Million
FHC Stake Holders
3
InvestorsCustomers – Procurers
Government/UN Agencies
Customers – UsersEmployees
Partners - NGO’s, Social
Marketing, Advocacy
Groups
Suppliers
Distributors
Society, Countries,
Regulatory Bodies
5
Adding New Team Capabilities
Sales and Marketing Capabilities Being Added withoutIncremental Headcount
• VP Sales and Marketing• US Sales and Marketing Director• Global Commercial Director• Consumer Marketing Manager
Operations Leader with Significant Global Male CondomExperience
FHC Company Brand
• Quality, Reliability, Safety
• Partnership in solving significant global issues– HIV/AIDS, other STIs– Poverty – Family planning– Female empowerment and rights
• Partnership in solving personal health issues– Non-hormonal birth control– Female empowerment/choice– Triple protection: Unwanted pregnancy, STIs, Fertility
6
• 8 years profitable• No debt• Accumulated cash for
acquisitions• Brazil tender for up to 50
million units / 25 million units ordered
• Strategy to accelerate growth in current markets and expand into new markets
• NOL’s utilized to reduce cash payments for income taxes
7
FY 2014 – 2013 Results
2014(millions)
2013(millions)
Units 42.5 54.8
Revenue $ 24.5 $ 31.5
Gross Margin $ 13.1 $ 17.5
Operating Income $ 3.9 $ 9.8
Tax Expense (Benefit) $ 1.5 ($ 4.4)
Net Income $ 2.4 $ 14.3
EPS – Without Valuation Allowance Adjustment
$ 0.10 $ 0.23
Cash from Operations before Capital Changes
$ 5.0 $ 10.4
2006 2007 2008 2009 2010 2011 2012 2013 20140
10
20
30
40
50
60
70Millions
25.9
34.740.2 38.9
61.6
32.9
19.6
100% sales of lower price, higher margin, next generation FC2
8
FC1 FC1 & FC2 FC2
54.8
CAGR 13.2 %
Unit Growth
42.5
FHC Growth Strategy
Invest in strategic growth initiatives to create long term shareholder value and
1. Grow FC Demand• Explore potential in high value consumer
market• Further develop existing global public
sector presence through sales and marketing activity
II. Diversify the Portfolio• Drive Company growth and improve the
consistency of revenues and earnings
10
Progress on Growth Strategy
• FC2 Growth Initiatives– New tender activities in focus countries– Consumer research completed, branding underway– Online store and other infrastructure put in place for
consumer launch
• Diversification– Over 75 products/companies evaluated– Ongoing discussions with top targets– Expected first deal announcement in calendar 2015
11
Consumer Market Research
• US women are generally unhappy with hormonal based birth control citing side effects as biggest issue
• Side effects most often cited include weight gain, mood disorder and unwanted hair growth
• The main option available to date for non-hormonal birth control has been male condoms. Many users report reduced pleasure with male condoms due to interruption, restriction, loss of sensation
13
Consumer Market Research
• Coming Soon: – New Brand– New Package– New Condom Colors – requires FDA pre-approval
14
Why FC2 Demand Will Continue To Grow
• Continued Global Focus on HIV– Feminization of AIDS – leading cause of death women
age 15-44– 35 million persons living with AIDS, 2.3 million newly
infected in 2012
• Exploding incidence of STIs around the world– 20M new cases every year in the US alone, half
occurring in young people aged 15-24
• Tapping into Consumer Market - Non-hormonal birth control alternative– Many US women report dissatisfaction with the side
effects of hormonal birth control
• Female Controlled Protection– Basic rights, education, opportunity
15
FHC Summary
• Stable, profitable company
• New strategy focused on driving Company growth
• Small percentage of total potential market reached to date = opportunity for growth
• Experienced leadership
16